Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:83

Review

Ellis, Samantha R.^1,5  Vierra, Aren T.¹  Millsop, Jillian W.²  Lacouture, Mario E.³  Kiuru, Maija^1,4 

[1] Univ Calif Davis, Dept Dermatol, 3301 C St,Ste 1450, Sacramento, CA 95816 USA

[2] Vacaville Med Ctr, Dept Dermatol, Permanente Med Grp, Vacaville, CA USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY 10021 USA

[4] Univ Calif Davis, Dept Pathol & Lab Med, Sacramento, CA 95816 USA

[5] PotozkinMD Skincare Ctr, Danville, CA USA

关键词: adverse event;    atezolizumab;    avelumab;    bullous pemphigoid;    checkpoint inhibitor;    CTLA-4;    cutaneous;    durvalumab;    immunotherapy;    ipilimumab;    lichenoid dermatitis;    nivolumab;    PD1;    PD-L1;    pembrolizumab;    rash;    skin;    toxicity;   

DOI  :  10.1016/j.jaad.2020.04.105

来源: Elsevier

【 摘 要 】

Antineoplastic agents that use the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein 1, or programmed cell death ligand 1 show improved and sustained responses in patients with cancer. However, these agents are associated with a plethora of adverse events, many manifesting in the skin. As the clinical application of cancer immunotherapies expands, understanding the clinical and histopathologic features of associated cutaneous toxicities becomes increasingly important to dermatologists, oncologists, and pathologists to ensure timely diagnosis and appropriate care. This review discusses cutaneous reactions to immune checkpoint inhibitors, focusing on histopathologic features.

【 授权许可】

Free